Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Aghemo, Alessio ^a   Grassi, Eleonora ^a   Rumi, Maria Grazia ^a   D'Ambrosio, Roberta ^a   Galmozzi, Enrico ^a   Degasperi, Elisabetta ^a   Castaldi, Davide ^b   Soffredini, Roberta ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; INORGANIC PYROPHOSPHATASE; ITPA PROTEIN, HUMAN; OLIGOPEPTIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HUMAN; INOSINE TRIPHOSPHATASE GENE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; ADVERSE EFFECTS; DRUG COMBINATION; EARLY DIAGNOSIS; FIBROSIS; GENETIC VARIABILITY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; FEMALE; FIBROSIS; GENETIC VARIATION; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84899714739     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095881     Document Type: Article

References (22)

1. European Association for Study of Liver (2014). EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60(2):392-420.
2. Aghemo A, Degasperi E, Colombo M (2013) Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. Dig Liver Dis 45(1):1-7.
3. Hézode C, Fontaine H, Dorival, Larrey D, Zoulim F, et al. (2013) Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 59(3):434-41.
4. Colombo M, Fernández I, Abdurakhmano D, Ferreira PA, Strasser SI, et al. (2013) Safety and on treatment efficacy of telaprevir: the early access program for patients with advanced hepatitis C. Gut DOI: 10.1136/gutjnl-2013- 305667.
5. Werner CR, Franz C, Egetemeyr DP, Malek NP, Laueret UM, et al. (2013) Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment. J Viral Hepat DOI: 10.1111/jvh.12145.
6. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, et al. (2013) Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 8(2):e55285.
7. Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, et al. (2010) Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 139(4):1181-9.
8. Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, et al. (2013) Inosine triphosphatase deficiency helps predict anemia, anemia management and response in chronic hepatitis C therapy. J Viral Hepat 20(12):858-66.
9. Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, et al. (2013) Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol 59(4):667-74.
10. Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, et al. (2011) Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 53(2):415-21.
11. Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24(2):289-93. (Pubitemid 26260021)
12. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, et al. (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29(12):1705-13. (Pubitemid 38091720)
13. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, et al. (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128(2):343-50. (Pubitemid 40439195)
14. Galmozzi E, Facchetti F, Degasperi E, Aghemo A, Lampertico P (2013) Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. J Virol Methods 187(2):271-3.
15. Hammond K, Jimmerson L, MacBrayne C, Ray M, Bushman L, et al. (2013) Increased plasma and intracellular ribavirin concentrations associated with telaprevir use. Rev Antiv Ther Infect dis 3:26.
16. Boglione L, De Nicoló A, Cusato J, Cariti G, Di Perri G, et al. (2014) Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. J Viral Hepat 21(4):260-3.
17. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, et al. (2010) ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 464(7287):405-8.
18. Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, et al. (2011) Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 40(4):1314-21.
19. Sulkowski MS, Roberts S, Afdhal N, Dusheiko G, Di Bisceglie AM, et al. (2011) Ribavirin dose modification in treatment-naïve and previously treated patients who received telaprevir combination treatment: No impact on sustained virologic response in phase 3. J Hepatol 56:S459-S460.
20. Romero-Gómez M, Berenguer M, Molina E, Calleja JL (2013) Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. J Hepatol 59(6):1323-30.
21. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, et al. (2013) Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 57(3):974-84.
22. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, et al. (2013) Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial. Gastroenterology 145(5):1035-1044.